<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This article reviews the strengths and limitations of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) as models of <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="?"><plain>Specifically, the article attempts to answer the following questions: Which clinical <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> can be modeled by iPSC-CM </plain></SENT>
<SENT sid="2" pm="?"><plain>How well can iPSC-CM model adult ventricular myocytes </plain></SENT>
<SENT sid="3" pm="?"><plain>What are the strengths and limitations of published iPSC-CM <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> models </plain></SENT>
<SENT sid="4" pm="?"><plain>What new mechanistic insight has been gained </plain></SENT>
<SENT sid="5" pm="?"><plain>What is the evidence that would support using iPSC-CM to personalize antiarrhythmic drug therapy </plain></SENT>
<SENT sid="6" pm="."><plain>The review also discusses the pros and cons of using the iPSC-CM technology for modeling specific genetic <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> disorders, such as <z:hpo ids='HP_0001657'>long QT syndrome</z:hpo>, <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada Syndrome</z:e>, or Catecholaminergic Polymorphic <z:hpo ids='HP_0004756'>Ventricular Tachycardia</z:hpo> </plain></SENT>
</text></document>